Mode
Text Size
Log in / Sign up

Response-adapted surgery after neoadjuvant immune checkpoint inhibitors improves pathologic complete response in mucosal HNSCCResponse-Adapted Surgery May Help Preserve Organs in Head Cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider response-adapted surgery after neoadjuvant ICIs to potentially improve pCR and enable surgical de-escalation.

This meta-analysis evaluates the impact of response-adapted surgery (RAS) following neoadjuvant immune checkpoint inhibitors (ICIs) compared to baseline-planned surgery (BPS) in patients with resectable mucosal head and neck squamous cell carcinoma (HNSCC). The analysis included 202 patients in the RAS group and 403 patients in the BPS group.

Key findings indicate that the RAS group achieved a significantly higher pathologic complete response (pCR) rate of 41.7% compared to 19.8% in the BPS group (P=.001). Other primary and secondary outcomes did not show statistically significant differences between the two groups. Specifically, the major pathologic response (MPR) was 59.6% for RAS and 48.5% for BPS (P=.245). Event-free survival (EFS) was 83.3% for RAS versus 82% for BPS (P=.751), and overall survival (OS) was 92.3% for RAS versus 91.4% for BPS (P=.839).

The authors note limitations including a small number of RAS studies (n=4) and the need for larger prospective studies. Despite these limitations, the authors suggest that RAS following neoadjuvant ICIs may enable surgical de-escalation with preserved oncologic outcomes and improved function in selected patients. The association between RAS and greater organ preservation and reduced need for mandibulectomy and free-flap reconstruction was noted, though further prospective data are required to confirm these clinical benefits.

How this fits prior evidence

This meta-analysis addresses a gap in the management of mucosal head and neck squamous cell carcinoma (HNSCC) by evaluating response-adapted surgery. While previous coverage noted that immune checkpoint inhibitor (ICI) combinations improve pathological response in gastric adenocarcinoma and triple-negative breast cancer, this study specifically examines the impact of surgery adaptation based on neoadjuvant ICI response in HNSCC. It provides evidence that RAS can significantly improve pCR rates compared to baseline-planned surgery.

Researchers looked at how patients with certain head and neck cancers responded to a specific treatment plan. They compared two methods: response-adapted surgery (RAS) and baseline-planned surgery (BPS). Both groups received immune checkpoint inhibitors before their surgery. The study looked at 605 patients in total to see if changing the surgical plan based on how the cancer reacted to treatment made a difference.

The results showed that patients who had the response-adapted surgery were more likely to achieve a pathologic complete response. However, there was no significant difference between the two groups regarding overall survival or event-free survival. While the data suggests that the adapted approach might help preserve organs and reduce the need for complex reconstructions, the evidence is currently limited.

Because the study included a small number of response-adapted cases, the results are not yet definitive. More large-scale studies are needed to confirm if this approach consistently improves outcomes. Patients should talk to their doctors to understand how these surgical options might apply to their specific diagnosis.

What this means for you:
Response-adapted surgery may help preserve organs in some head cancer patients, but more large studies are needed.

Common questions

What is the difference between response-adapted and baseline-planned surgery?

Baseline-planned surgery follows a set plan from the start. Response-adapted surgery (RAS) adjusts the surgical plan based on how the tumor reacts to neoadjuvant immune checkpoint inhibitors before the operation. The study found that RAS led to a higher pathologic complete response rate of 41.7% compared to 19.8% for baseline-planned surgery.

Does this new surgical approach improve survival rates?

The study did not find a significant difference in survival rates between the two groups. The overall survival rate was 92.3% for the response-adapted group and 91.4% for the baseline-planned group. Similarly, the event-free survival rates were 83.3% and 82% respectively, showing no significant difference between the two methods.

Can this treatment help preserve organs during surgery?

There is a reported link between response-adapted surgery and better organ preservation. The data suggests it may lead to a lower rate of mandibulectomy and a lower rate of free-flap reconstruction. However, because only four studies were included for the response-adapted group, more research is needed to confirm these findings.

Study Details

Study typeMeta analysis
Sample sizen = 202
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
INTRODUCTION: Recent encouraging outcomes with neoadjuvant immune checkpoint inhibitors (ICIs) in mucosal head and neck squamous cell carcinoma (HNSCC) have generated interest in surgical de-escalation. However, the oncologic safety of response-adapted surgery (RAS) and its ability to achieve survival outcomes comparable to baseline-planned surgery (BPS) remain uncertain. METHODS: A systematic search of the PubMed, EMBASE, Cochrane Library, and the Clinical Trials Registry for studies of neoadjuvant ICIs, with or without chemotherapy, in resectable mucosal HNSCC, that explicitly report surgical extent, between 2020-2025 was performed. Two independent reviewers extracted data following PRISMA guidelines. Main outcomes included major pathologic response (MPR), pathologic complete response (pCR), event-free survival (EFS), and overall survival (OS). Study-level proportions were pooled by random effects models. Heterogeneity was assessed by the I statistic. RESULTS: The comparative analysis consisted of 4 RAS studies (involving 202 patients) and 11 BPS studies (403 patients). The pooled overall EFS was 83.3% (76.9-88.2) for the former and 82% (75.2-87.2) for the latter (P=.751), and the respective pooled OS was 92.3% (87.5-95.3) and 91.4% (80.3-96.5) (P=.839). The pooled pCR rate was 41.7% (95% CI 5.4-48.4; I=.0) for RAS and 19.8% (95%CI 13.3-29.6; I=.62) for BPS (P=.001), while the MPR was not significantly different (59.6%, versus 48.5%, P=.245). RAS was associated with greater organ preservation and reduced need for mandibulectomy and free-flap reconstruction. CONCLUSIONS: RAS following neoadjuvant ICIs in mucosal HNSCC may enable surgical de-escalation with preserved oncologic outcomes and improved function in selected patients. Larger prospective studies are warranted.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.